YAHOO!: EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395

Press/Media: Research

Period18 May 2022

Media contributions

1

Media contributions

  • TitleEpiEndo: Successful Completion of Phase I Study for Lead Asset EP395
    Media name/outletYahoo!
    Media typeWeb
    Country/TerritoryUnited States
    Date18/05/22
    DescriptionREYKJAVIK, Iceland, May 18, 2022--(BUSINESS WIRE)--EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects.

    EP395, is the first of EpiEndo’s orally available, non-antibiotic macrolides or ‘Barriolides™’, to enter clinical development and will be targeting chronic obstructive pulmonary disease (COPD). EpiEndo is taking a novel approach to drug development for chronic respiratory diseases, focusing on enhancing the integrity of the epithelial cell layer in the lung to reduce disease-causing inflammation.
    URLhttps://www.yahoo.com/now/epiendo-successful-completion-phase-study-110000791.html
    PersonsSukh Singh
View all 1
View less

Keywords

  • respiratory disorders